Richard Hennings

Richard Hennings joined Synairgen as Chief Commercial Officer in March 2021. Richard was previously VP & Commercial Head of Verona Pharma from 2017 up to the $200M Ph 3 financing raise in July ‘20. Between 1999 & 2017 he held Commercial leadership roles at Gilead Sciences, Novartis & AstraZeneca. During his 8 year Gilead tenure Richard led expansion of respiratory & anti-viral portfolios in the EU & US markets, launching inhaled Cayston® for Cystic Fibrosis & HIV treatment Stribild®. During his subsequent AstraZeneca assignment, Richard led Antibiotic Zavicefta® EU/ LATAM launch readiness and divestment of the antibiotics business unit to Pfizer.